OSW Stock Analysis: OneSpaWorld Holdings | NASDAQ
Leisure | NASDAQ, USA | Market Cap: 2.772m USD | 12M Return: 26% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 26.8M
EPS Trend: 96.7%
Qual. Beats: 0
Rev. Trend: 97.9%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 8.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
OneSpaWorld Holdings Limited (OSW) operates health and wellness centers primarily onboard cruise ships and at destination resorts across the United States and internationally. The company provides a broad range of services including massage and body care, aesthetics, medi-spa treatments, acupuncture, fitness and personalized training, nutritional consultation, and hydro-therapies utilizing amenities such as infrared saunas, snow rooms, and cold plunge pools. It also retails branded products from partners including ELEMIS, Grown Alchemist, Kerastase, Keratin Complex, Thermage, Dysport, GoodFeet, Hyperice, and Megawhite teeth whitening. Founded in 2017, OneSpaWorld is headquartered in Nassau, Bahamas, and is classified within the Consumer Discretionary sector under Specialized Consumer Services.
The companys business model is largely B2B2C, generating revenue through long-term concession agreements with major cruise operators while delivering services and products directly to cruise passengers and resort guests. Performance is closely tied to the cruise industrys passenger volumes and onboard spending trends, making it a leveraged play on global leisure travel demand.
- Cruise passenger volumes and onboard spending recovery drive revenue
- New ship fleet additions expand exclusive cruise line partnership contracts
- Destination resort segment growth and margin expansion accelerate
| Net Income: 77.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -0.29 > 1.0 |
| NWC/Revenue: 8.78% < 20% (prev 6.06%; Δ 2.72% < -1%) |
| CFO/TA 0.12 > 3% & CFO 82.5m > Net Income 77.7m |
| Net Debt (86.4m) to EBITDA (120.0m): 0.72 < 3 |
| Current Ratio: 2.52 > 1.5 & < 3 |
| Outstanding Shares: last quarter (102.3m) vs 12m ago -2.64% < -2% |
| Gross Margin: 13.65% > 18% (prev 15.34%; Δ -1.69% > 0.5%) |
| Asset Turnover: 139.4% > 50% (prev 127.5%; Δ 11.96% > 0%) |
| Interest Coverage Ratio: 7.88 > 6 (EBIT TTM 94.1m / Interest Expense TTM 11.9m) |
| A: 0.12 (Total Current Assets 144.1m - Total Current Liabilities 57.2m) / Total Assets 709.9m |
| B: -0.33 (Retained Earnings -231.6m / Total Assets 709.9m) |
| C: 0.13 (EBIT TTM 94.1m / Avg Total Assets 709.3m) |
| D: 3.79 (Book Value of Equity 561.8m / Total Liabilities 148.1m) |
| Altman-Z'' = 4.61 = AA |
| DSRI: 1.01 (Receivables 49.3m/44.7m, Revenue 989.0m/903.4m) |
| GMI: 1.12 (GM 15.34% / 13.65%) |
| AQI: 0.96 (AQ_t 0.74 / AQ_t-1 0.77) |
| SGI: 1.09 (Revenue 989.0m / 903.4m) |
| TATA: -0.01 (NI 77.7m - CFO 82.5m) / TA 709.9m) |
| Beneish M = -2.86 (Cap -4..+1) = A |
As of July 16, 2026, the stock is trading at USD 26.45 with a total of 871,701 shares traded. Over the past week, the price has changed by +0.46%, over one month by +1.03%, over three months by +8.54% and over the past year by +25.99%.
Current recommended Stop Loss: 24.30 (which is 8.1% or 2.3 ATR below the current price).
OneSpaWorld Holdings has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy OSW.
- StrongBuy: 4
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 29.4 | 11.2% |
P/E Trailing = 36.4133
P/E Forward = 27.8552
P/S = 2.8412
P/B = 5.1828
Revenue TTM = 989.0m USD
EBIT TTM = 94.1m USD
EBITDA TTM = 120.0m USD
Long Term Debt = 82.8m USD (from longTermDebt, last quarter)
Short Term Debt = 1.75m USD (from shortTermDebt, last quarter)
Debt = 102.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 9.82m
Net Debt = 86.4m USD (calculated: Debt 102.4m - CCE 16.1m)
Enterprise Value = 2.86b USD (2.77b + Debt 102.4m - CCE 16.1m)
Interest Coverage Ratio = 7.88 (Ebit TTM 94.1m / Interest Expense TTM 11.9m)
EV/FCF = 44.13x (Enterprise Value 2.86b / FCF TTM 64.8m)
FCF Yield = 2.27% (FCF TTM 64.8m / Enterprise Value 2.86b)
FCF Margin = 6.55% (FCF TTM 64.8m / Revenue TTM 989.0m)
Net Margin = 7.85% (Net Income TTM 77.7m / Revenue TTM 989.0m)
Gross Margin = 13.65% ((Revenue TTM 989.0m - Cost of Revenue TTM 854.0m) / Revenue TTM)
Gross Margin QoQ = 15.12% (prev 11.11%)
Tobins Q-Ratio = 4.03 (Enterprise Value 2.86b / Total Assets 709.9m)
Interest Expense / Debt = 11.66% (Interest Expense 11.9m / Debt 102.4m)
Taxrate = 5.41% (4.44m / 82.1m)
NOPAT = 89.0m (EBIT 94.1m * (1 - 5.41%))
Current Ratio = 2.52 (Total Current Assets 144.1m / Total Current Liabilities 57.2m)
Debt / Equity = 0.18 (Debt 102.4m / totalStockholderEquity, last quarter 561.8m)
Debt / EBITDA = 0.72 (Net Debt 86.4m / EBITDA 120.0m)
Debt / FCF = 1.33 (Net Debt 86.4m / FCF TTM 64.8m)
Total Stockholder Equity = 551.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.95% (Net Income 77.7m / Total Assets 709.9m)
RoE = 14.09% (Net Income TTM 77.7m / Total Stockholder Equity 551.4m)
RoCE = 14.83% (EBIT 94.1m / Capital Employed (Equity 551.4m + L.T.Debt 82.8m))
RoIC = 13.94% (NOPAT 89.0m / Invested Capital 638.4m)
WACC = 9.29% (E(2.77b)/V(2.87b) * Re(9.23%) + D(102.4m)/V(2.87b) * Rd(11.66%) * (1-Tc(0.05)))
Discount Rate = 9.23% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 2.39 | Cagr: 0.92%
[DCF] Terminal Value 71.76% ; FCFF base≈65.6m ; Y1≈64.2m ; Y5≈64.8m
[DCF] Fair Price = 7.75 (EV 873.5m - Net Debt 86.4m = Equity 787.2m / Shares 101.5m; r=9.29% [WACC]; 5y FCF grow -2.90% → 2.50% )
EPS Correlation: 96.66 | EPS CAGR: 22.21% | SUE: 0.63 | # QB: 0
Revenue Correlation: 97.91 | Revenue CAGR: 11.09% | SUE: 2.03 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.28 | Chg30d=-1.41% | Revisions=+0% | Analysts=6
EPS next Quarter (2026-09-30): EPS=0.32 | Chg30d=-1.65% | Revisions=+17% | Analysts=6
EPS current Year (2026-12-31): EPS=1.14 | Chg30d=-0.87% | Revisions=+38% | GrowthEPS=+14.6% | GrowthRev=+7.2%
EPS next Year (2027-12-31): EPS=1.30 | Chg30d=-0.64% | Revisions=+29% | GrowthEPS=+14.2% | GrowthRev=+8.7%
[Analyst] Revisions Ratio: +32% (up=11, down=5)